Endocrine disruption test ERalpha-CALUX
Validated Method 2009
European Union Reference Laboratory for Alternatives to Animal Testing, Ispra, Italy
The ERalpha-CALUX test is an oestrogen receptor transactivation test that can be used to determine whether a substance has an (anti-)oestrogen effect.
The test is based on a human osteocarcinoma cell line (U2OS). The assay determines if a substance is to interact with the receptors for endogenous hormones; thus, early events within an adverse outcome pathway (AOP) related to endocrine disruption can be detected. The test can be used as part of an Integrated Test Strategy (ITS) or Integrated Test and Assessment Concept (IATA) to identify endocrine disrupters. Validated and regulatory approved under TM2009-11 (EU) by EURL ECVAM (TSAR list), OECD Test No. 455.
Prediction of the in vivo estrogenic activity of chemicals ERalpha-CALUX
EURL ECVAM
Added on: 07-02-2020
[1] https://tsar.jrc.ec.europa.eu/test-method/tm2009-11[2] https://www.oecd-ilibrary.org/environment/test-no-455-performance-based-test-guideline-for-stably-transfected-transactivation-in-vitro-assays-to-detect-estrogen-receptor-agonists-and-antagonists_9789264265295-en
